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Abstract
Chromosomal translocations between loci encoding MALT1 and c-IAP2 are common in MALT lymphomas. The resulting
fusion proteins lack the c-IAP2 RING domain, the region responsible for its ubiquitin protein ligase (E3) activity. Ectopic
expression of the fusion protein activates the canonical NF-kB signaling cascade, but how it does so is controversial and
how it promotes MALT lymphoma is unknown. Considering recent reports implicating c-IAP1 and c-IAP2 E3 activity in
repression of non-canonical NF-kB signaling, we asked if the c-IAP2/MALT fusion protein can initiate non-canonical NF-kB
activation. Here we show that in addition to canonical activation, the fusion protein stabilizes NIK and activates non-
canonical NF-kB. Canonical but not non-canonical activation depended on MALT1 paracaspase activity, and expression of
E3-inactive c-IAP2 activated non-canonical NF-kB. Mice in which endogenous c-IAP2 was replaced with an E3-inactive
mutant accumulated abnormal B cells with elevated non-canonical NF-kB and had increased numbers of B cells with a
marginal zone phenotype, gut-associated lymphoid hyperplasia, and other features of MALT lymphoma. Thus, the c-IAP2/
MALT1 fusion protein activates NF-kB by two distinct mechanisms, and loss of c-IAP2 E3 activity in vivo is sufficient to
induce abnormalities common to MALT lymphoma.
Citation: Conze DB, Zhao Y, Ashwell JD (2010) Non-Canonical NF-kB Activation and Abnormal B Cell Accumulation in Mice Expressing Ubiquitin Protein Ligase-
Inactive c-IAP2. PLoS Biol 8(10): e1000518. doi:10.1371/journal.pbio.1000518
Academic Editor: Douglas R. Green, St. Jude Children’s Research Hospital, United States of America
Received May 17, 2010; Accepted September 2, 2010; Published October 26, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by the Intramural Research Program of the National Institutes of Health, Center for Cancer Research, National Cancer Institute.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: 7AAD, 7-amino-actinomycin D; BAFF, B cell activating factor; BIR, baculovirus IAP repeat; GALT, gut-associated lymphoid tissue; IKK, IkB kinase;
LPS, lipopolysaccharide; LR-PCR, long-range polymerase chain reaction; MALT, mucosal associated lymphoid tissue; MAP, mitogen activated protein; MEF, murine
embryonic fibroblast; TNF-R1, Tumor Necrosis Factor Receptor 1; TRAF2, TNF Receptor Associated Factor 2
* E-mail: jda@pop.nci.nih.gov
Introduction
The defining characteristic of the IAP (Inhibitor of Apoptosis)
gene family is the presence of one or more baculovirus IAP
repeats (BIRs) (reviewed in [1]). These ,70 amino acid regions
mediate protein-protein interactions, and in the context of
adjacent sequences are responsible for the association of certain
IAP family members with caspases. There are eight mammalian
IAPs. Some IAPs also contain a RING motif that confers
ubiquitin protein ligase (E3) activity. c-IAP1 and c-IAP2 are such
RING-containing proteins that bind caspase-7 or -9 but, unlike
XIAP, do not inhibit their enzymatic activities [2]. c-IAP1 and c-
IAP2 also bind the adaptor protein TNF Receptor Associated
Factor 2 (TRAF2) and are components of the Tumor Necrosis
Factor Receptor 1 (TNF-R1) and 2 signaling complexes [3].
Upon TNF-R2 occupancy, c-IAP1, but not c-IAP2, ubiquitinates
TRAF2 and the mitogen activated protein (MAP) kinase kinase
kinase ASK1, resulting in the proteasomal degradation of all
three proteins, cessation of MAPK signaling, and an increased
susceptibility to cell death [4–6].
An emerging body of evidence has implicated the c-IAPs in
regulating the activation of the transcription factor NF-kB. NF-kB
can be activated by two distinct signaling mechanisms (reviewed in
[7,8]). The most common (the canonical pathway) depends on IkB
kinase (IKK) b-mediated phosphorylation of inhibitory IkB
proteins, leading to their ubiquitination and degradation. This
frees cytosolic NF-kB heterodimers to translocate to the nucleus
and regulate gene transcription. The second activating mechanism
(the non-canonical pathway) is downstream of a limited number of
receptors, including CD40, lymphotoxin b receptor, and BAFF
receptors, and involves the proteolytic removal of carboxy-
terminal ankyrin motifs in the NF-kB protein p100 to yield p52
[9,10]. p52/Rel B-dimers translocate to the nucleus and regulate
gene transcription [11]. Processing of p100 to p52 is dependent on
the sequential activation of the upstream kinases NIK (NF-kB-
inducing kinase) and IKKa [12–14]. Transient overexpression of
c-IAP2 in cells has been shown to induce the ubiquitination and
degradation of IkB, the essential antigen receptor NF-kB signaling
intermediate Bcl-10, and NIK [15–18]. Overexpression of c-IAP1
induced the ubiquitination and degradation of TRAF2 and NIK,
and its knockdown with silencing RNA impaired TNFa-induced
NF-kB activation [4,18–20].
Despite the (mostly in vitro) evidence for c-IAP regulation of
NF-kB, primary cells from c-IAP1 and c-IAP2 knockout mice
showed no obvious abnormalities in NF-kB activation [21,22].
However, studies using synthetic ‘‘Smac mimetics’’ that induce the
proteasomal degradation of c-IAP1 and c-IAP2, or siRNA to
knock down the remaining c-IAP molecule expressed in cells from
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proteins may work redundantly to promote TNF-a-induced NF-
kB activation and inhibit spontaneous non-canonical NF-kB
activation [18,20,23–25]. Binding of c-IAPs to TRAF2 brings
them into proximity with TRAF3-associated NIK. The result is a
repressive complex that causes ubiquitination and degradation of
NIK and maintains non-canonical NF-kB signaling in a basal state
[3,26,27]. Consistent with this, tandem deletions of the c-IAPs
have been associated with increased non-canonical NF-kB
signaling and the development of multiple myeloma [28,29], and
conditional deletion of TRAF2 and TRAF3 results in stabilization
of NIK, increased non-canonical signaling, and B cell hyperplasia
[30–33].
MALT (mucosal associated lymphoid tissue) lymphomas are
indolent neoplasms that have cytological features and bear cell
surface markers of marginal zone B cells, and typically invade
epithelial organs such as the gut and lung [34–36]. The molecular
events that contribute to MALT lymphomagenesis are not well
understood, but it is thought to involve the constitutive activation
of NF-kB [37]. A variety of chromosomal abnormalities are
associated with this disease; the most prevalent is a translocation,
t(11;18)(q21;q21), that results in the production of a fusion protein
containing the NH2-terminal (BIR-containing) fragment of c-IAP2
and the COOH-terminal portion of MALT1, a paracaspase
involved in antigen receptor signaling [38–40]. Ectopic expression
of this fusion protein in cell lines activates NF-kB [41], and
transgenic overexpression in mice results in an increase in
marginal zone B cells [42]. It is thought that the fusion protein
activates NF-kB via the canonical signaling pathway [43–46]. The
relevance of the different domains in the c-IAP2/MALT1 fusion
protein to the development of MALT lymphoma has not been
addressed.
Here we investigate the mechanism by which the c-IAP2/
MALT1 fusion protein contributes to the development of MALT
lymphoma. Ectopic expression of the fusion protein in cell lines
activated both the canonical and non-canonical NF-kB signaling
pathways, the former but not the latter being dependent on the
MALT1 paracaspase activity. Expression of a mutant c-IAP2 that,
like the c-IAP2 portion of the fusion protein, lacks E3 activity
activated non-canonical but not canonical NF-kB. Knockin mice
expressing this same c-IAP2 mutant in lieu of the wild type gene
accumulated abnormal B-cells that had elevated non-canonical
but not canonical NF-kB signaling, a cell-autonomous survival
advantage in vivo, and other features of MALT lymphomas. The
many points of similarity between mice expressing a c-IAP2 E3-
inactive mutant and patients expressing a c-IAP2 E3-inactive
MALT1 fusion protein suggests that the loss of this activity
activates non-canonical NF-kB and predisposes to malignancy.
Results
Loss of c-IAP2 E3 Activity and Non-Canonical NF-kB
Activation by the c-IAP2/MALT1 Fusion Protein
Ectopic expression of the c-IAP2/MALT1 fusion protein causes
p65 to translocate to the nucleus, evidence of canonical NF-kB
activation [43]. We assessed the mechanism of NF-kB induction in
293T cells transfected with the fusion protein (Figure 1A and 1B).
Expression of the c-IAP2/MALT1 fusion protein induced IkB
phosphorylation, as did a constitutively active form of IKKb
(IKKb-CA). Unlike IKKb-CA, however, c-IAP2/MALT1 result-
ed in little if any IkB degradation, suggesting that it is a much less
potent activator of canonical signaling. Notably, the c-IAP2/
MALT1 fusion protein, but not IKKb-CA, also increased the
levels of NIK and p52, hallmarks of non-canonical signaling.
Expression of MALT1 did not induce IkB phosphorylation or
degradation, or increase NIK or p52. Therefore, the fusion protein
can trigger both arms of the NF-kB signaling cascade.
The MALT1 portion of the c-IAP2/MALT1 fusion protein has
paracaspase activity, and it has been shown that expression of an
inactivating mutation resulted in approximately 2-fold less NF-kB
reporter activity than the paracaspase-active form [47]. We
compared NF-kB activation in 293T cells transfected with the
native sequence or paracaspase-inactive (c-IAP2/MALT1
C464A)
c-IAP2/MALT1 cDNA (Figure 1C). The canonical pathway, as
judged by IkB phosphorylation, was markedly reduced by the
mutation, but increases in the non-canonical pathway components
NIK and p52 were unaffected. The fusion protein lacks the c-IAP2
RING domain and therefore its E3 activity, and c-IAPs have been
shown to ubiquitinate NIK and repress non-canonical NF-kB
signaling [18,26,27]. In fact, expression of c-IAP2 lacking its
c-terminal half, as occurs in c-IAP2/MALT1 fusion proteins,
increased both NIK and p52 levels (Figure S1). To ask if this was
due specifically to the loss of E3 activity, we expressed c-IAP2 in
which a RING histidine that is critical for E3 activity was replaced
by alanine (c-IAP2
H574A), but the protein was otherwise intact
(Figure 1A) [48,49]. Expression of c-IAP2
H574A induced little if
any IkB phosphorylation but increased NIK and p52 levels
(Figures 1D and S1). These results show that the c-IAP2/MALT1
fusion protein activates both the canonical and non-canonical NF-
kB signaling cascades and that there are two distinct mechanisms.
The finding that expression of E3-defective c-IAP2 (Figure 1D) but
not MALT1 (Figure 1B) activated non-canonical NF-kB raised the
possibility that a similar mechanism might account for non-
canonical NF-kB activation by the c-IAP2/MALT1 fusion
protein.
Generation of the c-IAP2
H570A Knockin Mice
To investigate the consequences of expressing c-IAP2 lacking
E3 activity in vivo, we generated gene-targeted knockin mice that
express an E3-inactive mutant of c-IAP2 (c-IAP2
H570A) under the
control of the native regulatory regions (Figure 2A). ES cells that
had integrated the targeting vector were used to generate chimeric
mice that were crossed to the C57BL/6 background. The presence
of the H570A substitution in F1 offspring and subsequent
generations was assessed by long-template PCR followed by Spe
1 restriction endonuclease digestion. The expected fragment sizes
generated from the wild type allele are 4.9 and 0.7 kb, and those
Author Summary
MALT (mucosal associated lymphoid tissue) lymphomas
commonly express a mutant protein that contains a
portion of the ubiquitin protein ligase cellular Inhibitor
of Apoptosis 2 (c-IAP2) and a portion of the paracaspase
MALT1. Expression of this fusion protein activates the anti-
apoptotic transcription factor NF-kB, but how it does so
and whether or not this activity contributes to lympho-
magenesis is not known. Here we identify the mechanisms
by which the fusion protein activates NF-kB and show that
absence of c-IAP2 ubiquitin protein ligase activity in mice,
as is the case in patients that express the fusion protein,
results in spontaneous activation of NF-kB and many of
the phenotypic cellular features of MALT lymphoma. Our
findings demonstrate that c-IAP2 ubiquitin protein ligase
activity dampens constitutive NF-kB activity and maintains
B cell homeostasis, and provide genetic evidence that the
loss of this enzymatic activity in the fusion protein has a
major contributing role in MALT lymphomagenesis.
B Cell Abnormalities in c-IAP2 E3-Defective Mice
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H570A allele are 4.3 and 0.6 kb (Figure S2 and
Figure 2B). Acquisition of the mutant allele in c-IAP2
+/H570A and
c-IAP2
H570A/H570A mice caused the appearance of shorter
fragments in a gene dose-dependent manner.
Mutation of the Zn
2+-coordinating histidine in the c-IAP1,
c-IAP2, and XIAP RING domains [48,49] prevents autoubiqui-
tination and results in increased protein levels in cells transiently
expressing the corresponding cDNAs. Furthermore, under phys-
iologic conditions c-IAP1 downregulates c-IAP2 protein levels by
trans-ubiquitination and proteasomal degradation [21]; there does
not seem to be a reciprocal regulation of c-IAP1 by c-IAP2 [22].
To determine how c-IAP2 E3 activity might affect c-IAP levels,
splenocyte lysates were immunoblotted with an antiserum that
recognizes both c-IAP2 and c-IAP1 (Figure 2C) [50]. The
antibody detected a doublet in wild type cells, the upper and
fainter band being c-IAP2 and the lower and more prominent
being c-IAP1 [21]. There was a marked increase in c-IAP2
expression in c-IAP2
+/H570A cells and an even greater increase in
c-IAP2
H570A/H570A cells. In contrast, there was only a small
increase in the level of c-IAP1. We compared the susceptibility of
wild type c-IAP2 and the RING-less c-IAP2/MALT1 fusion
protein to ubiquitination-dependent degradation. Consistent with
a previous report [51], only levels of c-IAP2 increased in response
to proteasome inhibition, indicating that the lack of E3 activity
also stabilizes the fusion protein (Figure S3). Given that c-IAP2
expression is also regulated by c-IAP1-mediated ubiquitination
Figure 1. c-IAP2/MALT1 fusion protein activates canonical and non-canonical NF-kB signaling. (A) Schematic of c-IAP2, MALT1, c-IAP2/
MALT fusion protein, and other mutants used. * denotes the location of the inactivating mutations. (B, C, and D) c-IAP1/MALT fusion protein activates
canonical and non-canonical NF-kB signaling pathways. Lysates prepared from 293T cells that had been transfected with the indicated cDNAs for
24 h were immunoblotted with anti-FLAG, anti-phospho-IkB, anti-NIK, and anti-p52 antibodies. Because of differences in molecular weight, one can
use anti-FLAG to detect and distinguish between the NF-kB activating proteins (Activator: IKKb-CA, c-IAP2/MALT1, c-IAP2
H570A, and MALT1) and IkB.
Some lanes were reordered for clarity. b-actin expression was used as a loading control. * denotes a non-specific band.
doi:10.1371/journal.pbio.1000518.g001
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is required to maintain c-IAP2 at physiologic levels.
B Cell Hyperplasia, Marginal Zone B Cell Accumulation,
and Enlarged GALT in c-IAP2
H570A/H570A Mice
Homozygous c-IAP2 knockin mice were viable, fertile, and
displayed no obvious phenotypic abnormalities. Analysis of peri-
pherallymphoidorgansin6–7-month-oldc-IAP2
H570A/H570Amice,
however, revealed a number of abnormalities. Unlike the spleen,
cell numbers of pooled peripheral lymph nodes (axial, brachial,
superficial cervical, and inguinal) as well as mesenteric lymph nodes
were markedly increased (Figure 3G, A, and D). There was a
reduction in the percentage of T cells with a corresponding increase
inthepercentage ofB (B220
+) cells(Figure 3B,E,and H).The result
was approximately a 5-fold and 4-fold increase in the absolute
number of pooled and mesenteric lymph node B cells, respectively,
and a smaller (2-fold) increase in T cell number (Figure 3C and F).
The CD4
+:CD8
+ T cell ratio in c-IAP2
H570A/H570A mice was
normal (unpublished data). c-IAP2
H570A/H570A lymphocytes had an
unactivated phenotype, with normal levels of B7.1 and I-A
b (B cells)
and CD25 and CD69 (T cells) (unpublished data). Two- to three-
month-old c-IAP2
H570A/H570A mice also had increases in lymph
node B cells, although to a lesser extent than older animals (Figure
S4). Analysis of B and T cell precursors in bone marrow and
thymus, respectively, revealed no abnormalities. Among splenic B
cells there was reproducibly an approximately 3-fold increase in
the percentage of cells with a marginal zone phenotype
(CD21
hiCD23
2), with a compensatory decrease in the percentage
of follicular (CD21
intCD23
hi) and immature (CD21
2CD23
2)B
cells (Figure 3J). Although lymph nodes normally have few B cells
with a marginal zone phenotype [52], there was a small increase in
these cells in c-IAP2
H570A/H570A lymph nodes. Circulating IgA was
increased approximately 3-fold in c-IAP2
H570A/H570A mice, and
there were highly statistically significant increases in IgM and IgG3,
and a reduction in IgG1 as well (Figure 4). No statistically significant
changes were found in IgG2b and IgE levels.
B cell hyperplasia, particularly of marginal zone B cells, in gut-
associated lymphoid tissue (GALT) and lung is a feature of MALT
lymphomas [34,36]. Gross examination revealed that c-IA-
P2
H570A/H570A mice had enlarged GALT and mesenteric lymph
nodes, which was confirmed by histological evaluation (Figure 5A).
There were also mild to moderate lymphocytic infiltrates in the
lung (Figure 5B), with no evidence of neoplasia in either organ.
Despite the increased size of the GALT in c-IAP2
H570A/H570A
mice, immunohistochemistry and flow cytometric analysis of both
wild type and c-IAP2
H570A/H570A GALT revealed primarily B cells
with a follicular phenotype (Figure 5C and 5D), organized T-cell-
enriched areas (compare Figure 5C with Figure S5), and no
evidence of cellular activation (unpublished data). The lympho-
cytic infiltrates in the lungs of the c-IAP2 knockin mice also
consisted of B cells and T cells (unpublished data). Taken together,
these results demonstrate that mice with catalytically inactive
c-IAP2 acquire a lymphoid phenotype that shares many features
with MALT lymphomas.
Enhanced Survival and Proliferation of c-IAP2
H570A/H570A
B Cells In Vitro and In Vivo
The increase in B cell numbers in vivo could be due to
decreased death, increased expansion, or a combination. Suscep-
tibility to cell death was determined by culturing splenocytes in the
absence of growth or survival factors and quantifying cell viability
of B220
+ and TCRb
+ cells by measuring 7-AAD incorporation
(Figure 6A). c-IAP2 knockin B cells died more slowly than wild
type cells, with 10%–15% still viable even after 64 h, compared to
3% for wild type cells. Addition of BAFF or agonistic anti-CD40
partially rescued the survival of B cells of both genotypes with
similar dose-response curves (Figure 6B and unpublished data).
There was no difference between the genotypes with regard to T
cell survival (Figure 6A). Proliferative ability was addressed by
stimulating purified B cells with anti-m F(ab9)2 or lipopolysaccha-
ride (LPS) and measuring
3H-thymidine incorporation (Figure 6C).
c-IAP2
H570A/H570A B cells had enhanced responses to both
stimuli, with approximately a 3-fold shift in the dose response
curve toward lesser concentrations of stimulus compared to wild
type cells. During the course of the proliferation assays therewere
no differences between the two genotypes with regard to cell
death (unpublished data). To determine if these in vitro
observations correspond to B cell behavior in vivo, experiments
were performed in which a mixture of wild type and c-IAP2
knockin splenic B cells was adoptively transferred into RAG2-
deficient mice (Figure 6D). Although equal numbers of cells of
each genotype were injected, after 45 d a 3-fold (lymph node) to
5-fold (spleen) preponderance of c-IAP2 knockin B cells was
observed. These results show that the absence of c-IAP2 E3
activity in B cells results in a cell-intrinsic abnormality that
increases their capacity to survive and/or proliferate in vitro and
in vivo.
Spontaneous Non-Canonical NF-kB Activation in
c-IAP2
H570A/H570A Cells
Ectopic expression of a c-IAP2/MALT1 fusion protein
spontaneously activates NF-kB, as does depletion of c-IAPs with
Smac mimetics or silencing siRNAs [18,25,26,38,41,53,54]. We
therefore asked if selective loss of c-IAP2 E3 activity, in an
Figure 2. Generation of c-IAP2
H570A/H570A mice. (A) Site-directed
mutagenesis of the Zn
2+-coordinating histidine residue in the RING
domain of c-IAP2. Lower and upper case letters denote the nucleotide
and corresponding amino acid sequence, respectively, before and after
mutagenesis. The bolded amino acids highlight the histidine to alanine
replacement, and the italicized nucleotides highlight the nucleotide
substitutions. The box depicts the novel Spe1 restriction endonuclease
site. (B) Spe1 endonuclease digestion of PCR products amplified from
wild type (+/+), c-IAP2
+/H570A (+/mut), and c-IAP2
H570A/H570A (mut/mut)
tail DNA. SpeI digestion of the PCR fragment amplified from the wild
type (+) allele generates 4.9 and 0.7 kb fragments and the c-IAP2
H570A
(mut) allele 4.3, 0.7, and 0.6 kb fragments. (C) c-IAP expression in +/+,
+/mut, and mut/mut splenocytes was determined by immunoblot using
an antiserum that recognizes both c-IAP1 and c-IAP2. b-actin expression
was used as a loading control.
doi:10.1371/journal.pbio.1000518.g002
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H570A/H570A mice. Cellularity of pooled axial, brachial, superficial cervical,
and inguinal lymph nodes (Pooled LNs) (A), mesenteric lymph node (MLN) (D), and spleen (G) in wild type (+/+; n=3) and c-IAP2
H570A/H570A (mut/mut;
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PCR found that transcripts for NF-kB-responsive genes encoding
GADD45b,I kB, c-IAP2, and ferritin heavy chain were elevated in
c-IAP2
H570A/H570A B cells (Figure 7A) [15,55–57]. There was no
increase, however, in the expression of Bcl-2, a gene product that
has been reported to increase in response to canonical but not
non-canonical NF-kB activation [58,59], raising the possibility
that NF-kB activation in c-IAP2
H570A/H570A B cells was pathway-
specific. Activation of the canonical pathway was assessed by
measuring IkB levels and its state of phosphorylation. IkB levels
were similar to or perhaps slightly increased in c-IAP2
H570A/H570A
B cells (Figure 7B) and murine embryonic fibroblasts (MEFs)
(Figure 7C) compared to wild type cells. More importantly,
there was no increase in spontaneously phosphorylated IkBi n
c-IAP2
H570A/H570 cells, arguing against spontaneous canonical
NF-kB activation. In contrast, the levels of both NIK and p52
were elevated in knockin B cells (Figure 7D) and MEFs (Figure 7E).
The levels of TRAF2 and TRAF3, two components of a c-IAP-
containing inhibitory complex thought to degrade NIK [26,27],
were unaffected by the loss of c-IAP2 E3 activity (unpublished
data). In T cells, the amount of NIK was lower in wild type T than
wild type B cells, and there was little increase in T cells expressing
E3-inactive c-IAP2 (Figure 7D). There was correspondingly
little increase in p52, although a small amount was detected in
c-IAP2
H570A/H570A T cells. Together, these results indicate the E3
activity of c-IAP2 is required to inhibit constitutive non-canonical
NF-kB activation in B cells, MEFs, and to a much lesser degree, T
cells.
n=3) mice. The error bars represent the standard error of the mean. T (TCRb
+B220
2), B (TCRb
2B220
+), and non-T and non-B cell (TCRb
2B220
2)
distribution in pooled LNs (B), MLN (E), and spleen (H) of +/+ and mut/mut mice determined by flow cytometry. Numbers represent the percentage of
cells in each quadrant. Absolute number of T, B, and non-T/non-B cells in pooled LNs (C), MLN (F), and spleen (I) of +/+ and mut/mut mice. For the
pooled lymph node, the absolute number was divided by the total number of lymph nodes harvested. The error bars represent the standard error of
the mean. (J) Distribution of immature (CD23
2CD21
2), follicular (CD23
+CD21
int), and marginal zone (CD23
2CD21
+) B cells (gated on B220
+ cells) in
spleen (Spl), pooled LNs, and MLN. Numbers represent the percent positive in each gate.
doi:10.1371/journal.pbio.1000518.g003
Figure 4. Serum immunoglobulin levels in c-IAP2
H570/H570A mice. Wild type (+/+) and c-IAP2
H570A/H570A (mut/mut) mice were 8–10-wk-old,
each dot represents the titer for an individual mouse, and the horizontal lines indicate the mean titer for each genotype.
doi:10.1371/journal.pbio.1000518.g004
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2/2
and c-IAP2
H570A/H570A cells, only the latter has increased
spontaneous NF-kB activation. Because c-IAP1 also binds
TRAF2, which is essential for c-IAP-mediated repression of the
non-canonical signaling cascade [26], the results are consistent
with the possibility that the E3-defective c-IAP2 competes with
Figure 5. Lymphocytic infiltrates in the lungs and GALT hyperplasia in c-IAP2
H570A/H570A mice. Sections of GALT (A) and lung (B) from
wild type (+/+) and c-IAP2 knockin (mut/mut) mice stained with hematoxylin and eosin. Both tissues are presented at 86magnification and the bar
denotes 100 mm. Arrows highlight the areas containing the infiltrating lymphocytes in the lungs of c-IAP2
H570A/H570A mice. (C) B cell distribution in
GALT of +/+ and mut/mut mice. (D) Distribution of immature (CD23
2CD21
2), follicular (CD23
+CD21
int), and marginal zone (CD23
2CD21
+) B cells
(gated on B220
+ cells) in GALT of +/+ and mut/mut mice. Numbers represent the percent positive in each gate.
doi:10.1371/journal.pbio.1000518.g005
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H570A/H570A is able to bind
TRAF2 at least as well as the wild type protein (Figure S6). To ask
if the c-IAP2 RING mutant interfered with endogenous c-IAP1,
c-IAP2-specific siRNA was used to knock down c-IAP2 in wild
type and c-IAP2 knockin MEFs (Figure 7F). As seen in splenocytes
(Figure 2C), there was a large increase in c-IAP2 and a small
increase in c-IAP1 levels in c-IAP2 knockin MEFs (Lanes 1 and 3).
Transfection of wild type MEFs with c-IAP2 siRNA specifically
reduced c-IAP2 but had little if any effect on the levels of p52. In
contrast, knockdown of c-IAP2 in c-IAP2
H570A/H570A MEFs
resulted in a substantial reduction of p52 levels. To determine if
c-IAP2
H570A interferes with c-IAP1-mediated ubiquitination/
degradation of NIK, 293T cells were co-transfected with NIK
and c-IAP1, with or without c-IAP2
H570A (Figure 7G). Consistent
with previous reports [18,26], expression of c-IAP1 reduced NIK
to undetectable levels; this was prevented by co-expression of E3-
inactive c-IAP2. Thus, the E3-defective c-IAP2
H570A can inhibit
constitutive c-IAP1-mediated ubiquitination/degradation of NIK
and de-repress the non-canonical signaling cascade.
Discussion
Unmanipulated mice deficient for c-IAP1 and c-IAP2 have no
obvious phenotypic abnormalities [21,22], which has made it
difficult to ascribe a physiologic role to these proteins in vivo.
Recent studies have suggested that redundancy among the c-IAPs,
at least with regard to NF-kB activation, could account for the lack
of apparent abnormalities [18,25,26]. If so, this could be an even
bigger factor in c-IAP1 knockout mice, in which c-IAP2 levels are
elevated because it is no longer ubiquitinated by c-IAP1 and
targeted for degradation [21]. c-IAP1 is not elevated in cells from
c-IAP2-deficient mice [22], suggesting that even normal c-IAP1
levels are sufficient to compensate for the loss of c-IAP2. In
contrast to the c-IAP2 knockout animals, we have found that
substitution of wild type c-IAP2 with an E3-defective point
mutation does result in constitutive NF-kB activation and
abnormal B cell accumulation. This is likely because the
endogenous c-IAP1 is unable to compensate for the lack of
c-IAP2 E3 activity. The N-terminal BIR-containing region of both
proteins binds to TRAF2, a prerequisite for c-IAP-mediated NIK
ubiquitination [18,26]. Furthermore, only one c-IAP molecule can
bind one TRAF2 trimer at a time [60]. We found that
overexpressed c-IAP2
H570A/H570A interferes with c-IAP1-mediated
degradation of NIK and that knockdown of the c-IAP2 mutant
restored repression of non-canonical NF-kB. These data argue
that the mutant c-IAP2 prevented c-IAP1 from associating with
the repressive complex. The c-IAP2
H570A/H570A mice therefore
represent an example in which replacement of the endogenous
gene with an inactive form, but not a complete knockout, can
reveal normal function.
Abnormal B cell expansion has been observed in a number of
animal models in which NF-kB activity is chronically elevated. For
example, overexpression of B cell activating factor (BAFF) or NIK,
both of which lead to non-canonical NF-kB activation, results in B
cell hyperplasia with increased numbers of CD23
loCD21
hi B cells
[59,61]. Similarly, mice lacking either TRAF2 or TRAF3 in B
cells have elevated non-canonical NF-kB, an expanded B cell
compartment, increased numbers of cells with a marginal zone
phenotype, and elevated serum immunoglobulins [31–33].
TRAF2 and TRAF3 are adaptor molecules downstream of BAFF
receptors that constitutively form a complex with c-IAP1, c-IAP2,
and NIK [26,27]. These associations result in c-IAP-dependent
ubiquitination of NIK and its proteasomal degradation, which is
thought to maintain the non-canonical NF-kB activation pathway
Figure 6. c-IAP2
H570A/H570A B cells are more sensitive to
proliferative stimuli and survive longer in vitro. (A) Splenocytes
from wild type and c-IAP2
H570A/H570A mice were cultured for the
indicated times and the percentage of viable B and T cells was
quantitated by staining with anti-B220, anti-TCRb, and 7AAD. The
experiment was performed in triplicate and the error bars represent the
standard error of the mean. (B) Purified B cells were incubated with or
without BAFF or agonistic anti-CD40 for 66 h and cell viability was
determined as in (B). For the assessment of BAFF sensitivity, the percent
viability of untreated cells was subtracted from the percent viability at
each concentration of BAFF and the results are displayed as the increase
in percent viable cells. (C) IgM- and LPS-induced proliferative responses
of wild type (+/+) and c-IAP2
H570A/H570A (mut/mut) B cells. Purified B
cells were cultured in vitro with the indicated concentrations of anti-m
(Fab9)2 or lipopolysaccharide (LPS) for 48 h, pulsed with
3H-thymidine,
and harvested 18 h later. The experiment was performed in triplicate
and the error bars represent the standard error of the mean. (D)
Adoptive transfer of equal numbers of splenic wild type (wt; CD45.1
+)
and c-IAP2
H570A/H570A (mut; CD45.2
+) B cells into RAG2-deficient mice.
Forty-five days later splenocytes and lymphocytes were prepared and
the ratio of mut/wt B cells recovered was calculated by dividing the
percentage of mut (B220
+CD45.2
+) cells by the percentage of wt
(B220
+CD45.1
+) cells.
doi:10.1371/journal.pbio.1000518.g006
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TRAF2 and TRAF3 in c-IAP2
H570A/H570A mice, NIK levels and
NF-kB activity were increased, and the mice developed age-
dependent B cell hyperplasia in a manner similar to BAFF
and NIK transgenic mice, or TRAF2 and TRAF3 knockout mice
[31–33,59,61]. The data are all consistent with the notion that
Figure 7. Elevated non-canonical NF-kB activation in c-IAP2
H570A/H570A cells. (A) NF-kBt a r g e tg e n ee x p r e s s i o ni nW T( +/+) and c-IAP2
H570A/H570A
B cells determined by real-time PCR. Bars represent the mean increase of each mRNA in c-IAP2
H570A/H570A cells from three independent experiments. The
errorbars representthestandarderrorofthemean.(B)Immunoblottingofphospho-IkBa n dI kBi nl y s a t e so f+/+andc-IAP2
H570A/H570A (mut/mut) B cells. b-
actin expression was used as a loading of control. (C) Immunoblotting of phospho-IkBa n dI kB levels in lysates of unstimulated +/+ andmut/mut MEFsasin
(B). Lysates of cells stimulated with TNF-a (10 ng/ml for 5 min) were blotted in parallel as a positive control for the phospho-IkB antibody. (D)
Immunoblotting of NIK and p52 in lysates prepared from +/+ and mut/mut B and T cells. b-actin expression was used as a loading of control. (E)
Immunoblotting of NIK and p52 in lysates prepared from +/+ and mut/mut MEFs as in (D). (F) Knockdown of c-IAP2 in +/+ and mut/mut MEFs. Cells were
transfected with non-targeting (NT) or c-IAP2 siRNA (C2) for 24 h, harvested, and lysed. c-IAP2 and p52 levels were determined by immunoblot. b-actin
expressionwasusedasaloadingofcontrol.Thelaneshavebeenreorderedforclarity.(G)293Tcellsweretransfectedwithexpressionvectorscontainingthe
indicated cDNAs and immunoblotted for the respective peptide tags and b-actin.
doi:10.1371/journal.pbio.1000518.g007
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for regulating constitutive NF-kB activity and B cell homeostasis.
It is widely believed that the c-IAP2/MALT1 protein is
pathogenic because it activates the canonical NF-kB signaling
pathway [37]. A variety of mechanisms have been suggested,
including proteolytic cleavage of A20, a negative regulator of NF-
kB activation, ubiquitination of NEMO, binding of the fusion
protein to lysine 63-linked polyubiquitinated NEMO, and the
failure of the fusion protein to degrade Bcl-10 [37]. However, a
potential role for non-canonical NF-kB activation has not been
explored. We have found that the c-IAP2/MALT1 fusion protein
activates both canonical and non-canonical signaling pathways,
and activation of the latter in mice is sufficient to promote the
development of features common to MALT lymphoma. Our
results are in agreement with a report that overexpression of the
fusion protein in 3T3 cells resulted in an NF-kB complex that was
supershifted with antibodies to RelB [62]. Interestingly, introduc-
tion of a Bcl-10 transgene, which mimics the MALT lymphoma-
associated t(1;12)(p22;q32) chromosomal translocation that dereg-
ulates Bcl-10, results in marginal zone B cell hyperplasia and
elevated non-canonical as well as canonical NF-kB signaling [63].
It is noteworthy that mice lacking the COOH-terminal ankyrin
domain of p100, which results in constitutive activation of p52,
develop B cell hyperplasia and enlarged GALT. Thus, activation
of the non-canonical pathway may be a major contributor to the
development of MALT lymphoma. The development of MALT
lymphoma-like abnormalities in the c-IAP2 E3-defective mice
raises a cautionary note that drugs that reduce c-IAP levels, such
as SMAC mimetics, may have unintended side effects due to
activation of non-canonical NF-kB signaling, especially if admin-
istered chronically.
Materials and Methods
Mice and Reagents
RAG2-deficient and CD45.1 congenic mice were obtained from
the Jackson Laboratory. All restriction endonucleases were
obtained from New England Biolabs. pCMV9 containing
carboxy-terminal myc-tagged human NIK cDNA was obtained
from Nobuhiko Kayagaki and Vishva Dixit (Genentech) and
pRK5 containing Flag-tagged human c-IAP2 and c-IAP2/
MALT1 was obtained from Xiaolu Yang (University of Pennsyl-
vania). pRK5-Flag-tagged human c-IAP2
H574A and pRK5-Flag-
tagged human c-IAP2/MALT1
C464A were generated by site
directed mutagenesis using the primers 59-GTCCATAGTGTT-
TATTCCTTGTGGTCATCTAGTAGTATGCAAAGATTGT-
GC-39,5 9-GCACAATCTTTGCATACTACTAGATGACCA-
CAAGGAATAAACACTATGGAC-39,5 9-GACTTAATGTGT-
TCTTATTGGATATGGCTAGGAAAAGAAATGACTACGA-
TGATAC-39,5 9-GTATCATCGTAGTCATTTCTTTTCCTA-
GCCATATCCAATAAGAACACATTAAGTC-39, respectively,
and the QuickChange mutagenesis system from Stratagene.
pRK5-Flag-tagged human c-IAP2
DCARD-RING was generated by
cloning a PCR product amplified from human c-IAP2 cDNA into
pRK5 that already contained cDNA encoding the Flag-tag using
the primers 59-GCTCGTGAATGCGGGATCCTCTAGAAAC-
ATAGTAGAAAACAGC-39 and 5-GCTGCAACGTAAGCTT-
TCATTCATTTGATTCTTTTTCCTCAGTTGC-39, BamH1
and HindIII. Presence of the mutations was confirmed by direct
sequencing. pCMV-Tag2 murine c-IAP2 has been described [21].
GST-tagged murine c-IAP2 was obtained by subcloning into
pGEX-6P-1 (Amersham). GST-tagged murine c-IAP2
H570A was
generated by site directed mutagenesis using primers that have
been described [21]. Myc-tagged murine c-IAP1 was obtained by
subcloning into pCMV-Tag5 (Clontech). IKKb-CA has been
described [64]. pCMV4 containing Flag-tagged IkB cDNA was
obtained from Dean Ballard (Vanderbilt University). The anti-c-
IAP antibody was obtained from Herman Chung and Bob
Korneluk (Apoptosis Research Center, Children’s Hospital of
Eastern Ontario), anti-NIK and anti-p52 from Cell Signal-
ing Technologies, anti-phospho-IkB and anti-IkB from Santa
Cruz, and anti-FLAG and anti-b-actin from Sigma. Anti-CD40
(HM40-3) was obtained from BD Biosciences. BAFF was obtained
from Peprotech. The fluorescently labeled antibodies used for
analysis of lymphoid populations in the thymus, bone marrow,
lymph node, and spleen by flow cytometry were obtained from BD
Biosciences. The Mouse Immunoglobulin Isotype Panel (Southern
Biotech) was used to quantify the serum immunoglobulin titers for
IgM, IgG1, IgG2b, IgG3, and IgA. The OptEIA Set Mouse IgE
(BD Biosciences) was used to quantify the amount of serum IgE.
The anti-B220/CD45R and anti-CD3 used from B and T cell
immunohistochemistry were purchased from BD Biosciences and
Serotec, respectively. The B cell and T cell enrichment kits were
obtained from Stemcell Technologies. For some experiments B
cells were purified using the Mouse B cell Recovery Column Kit
from Cedarlane Laboratories Ltd. The primer sequences used in
the quantitative PCR are as follows, GADD45b 59 (59-CTG-
CCTCCTGGTCACGAA-39), GADD45b 39 (59-TTGCCTCTG-
CTCTCTTCACA-39), IkB5 9 (59-TCACGGAGGACGGAGAC-
TCG-39), IkB3 9 (TGGAGATGCTGGGGTGTGC), ferritin
heavy chain 59 (59-GGAGTTGTATGCCTCCTACGTCT-39),
ferritin heavy chain 39 (59-TGGAGAAAGTATTTGGCAAAG-
TT-39), c-IAP2 59 (59-TATTTGTGCAACAGGACATTAG-
GAGT-39), c-IAP2 39 (TCTTTCCTCCTGGAGTTTCCG), Bcl-
25 9 (59-GTACCTGAACCGGCATCTG-39), and Bcl-2 39 (59-
GGGGCCATATAGTTCCACAA-39). The HPRT primers have
been described [65]. c-IAP2 siRNA has been described [26] and
was modified to Stealth RNAi siRNA. The sequences of the
oligonucleotides are 59-AAGUGGUAGGGACUUGUGCUCAA-
AG-39 and 59-CUUUGAGCACAAGUCCCUACCACUU-39.
Gene Targeting and Generation of the c-IAP2
H570A/H570A
Mice
The BamH1-EcoR1 and EcoR1-EcoR1 recombination arms used
to generate the c-IAP2
H570A targeting construct were obtained from
BAC-DNA (clone 239-13P; Research Genetics) using the respective
endonucleases and subcloned into shuttle vectors. To insert the silent
mutation in the neighboring leucine codon introducing a novel Spe1
restriction endonuclease site and then replace the histidine codon
with an alanine codon, the BamH1-Ecor1 arm was sequentially
mutagenized using mutagenic primers 59-CATCGTGTTCA-
TTCCCTGTGGCGCACTAGTCGTGTGCAAAGACTGCG-39
and 59-CGCAGTCTTTGCACACGACTAGTGCGCCACAGG-
GAATGAACACGATG-39,a n dt h e n5 9-CATTCCCTGTGGC-
CATCTAGTCGTGTGCAAAGACTGC-39 and 59-GCAGTCT-
TTGCACACGACTAGATGGCCACAGGGAATG-39 using the
QuickChange mutagenesis system from Stratagene. The presence of
H570A in exon 9 and absence of other spontaneous mutations in the
other exons were confirmed by direct sequencing. After subcloning
both recombination arms into a vector containing a neomycin
cassette flanked by two loxP recombination sites, the resultant
targeting vector was linearized with Not1 and transfected into ES
cells. Stable transfectants were screened by southern blotting and
long-range polymerase chain reaction (LR-PCR) coupled with
Spe1 restriction endonuclease digestion. The primers used to screen
the c-IAP2
H570A/H570A mice were obtained from Invitrogen and
their sequence was 59 CGAAAAAGATGCCCATCTACTC
AG-39 and 59-TATCCCTAAAATGTCATCCAATAAATAA-
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construct at the c-IAP2 locus was injected into blastocytes to generate
chimeric mice. F1 offspring of the chimeric mice were backcrossed
6 additional times to the C57BL/6 (B6) background and then
c-IAP2
+/H570A were interbred to obtain c-IAP2
H570A/H570A mice. B6
mice bred in the CRC Vivarium (NIH) were used as controls for all
experiments.
Ethics Statement
All animal experimental procedures were approved by the
Animal Care and Use Committee of the National Cancer Institute.
LR-PCR and Real-Time PCR
The fragment spanning the recombination arm containing c-
IAP2
H570A was amplified from tail DNA using buffer 3 from the
Expand Long Template PCR System (Roche) and the c-IAP2
locus 59 and c-IAP2 locus 39 primers, digested with Spe1, and
resolved by agarose gel electrophoresis. Total RNA was isolated
from purified B cells using the Utraspec RNA isolation reagent
(Biotecx laboratory) and reverse transcribed using Superscript II
Reverse Transcriptase kit (Invitrogen) following the manufactur-
ers’ protocol. The amount of ferritin heavy chain, IkB, c-IAP2,
GADD45b, Bcl-2, and hypoxanthine phosphoribosyltransferase
(HPRT) mRNA was quantified using the respective primers,
SYBR Green PCR Master Mix (Applied Biosystems), and the
7500 Real Time PCR System (Applied Biosystems). The values
were normalized to HPRT and the percent increase relative to
wild type was calculated by dividing the c-IAP2 knockin values by
the wild type values.
Cell Preparation, Surface Staining, and Purification
Bone marrow, thymus, spleen, lymph nodes (superficial cervical,
axillary, brachial, inguinal, and mesenteric) and GALT were
harvested from wild type and c-IAP2
H570A/H570A mice, disrupted
by teasing, and total cell suspensions made by gently mashing the
debris through 40 mM nylon mesh (BD Biosciences). The cells
were counted and the distribution of lymphoid populations in each
organ was determined by cell surface staining and flow cytometry.
B and T cells were purified from spleen and lymph nodes from
wild type and c-IAP2
H570A/H570A mice using B and T cell
enrichment kits following the manufacturer’s protocol. The purity
was determined by cell surface staining and flow cytometry, and
for all experiments, greater than 90%. In some experiments B cells
and splenocytes were cultured in RPMI supplemented with 10%
fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin,
2 mM L-glutamine, and 50 mM-b-mercaptoethanol. MEFs were
prepared from day 13.5 embryos as described [66] and maintained
in Dulbecco’s Modified Eagle’s medium supplemented with 10%
fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin,
2 mM L-glutamine, and 50 mM-b-mercaptoethanol.
Cell Death and Proliferation
For quantifying cell death, splenocytes (7.5610
5 cells/ml) were
incubated in vitro, stained with fluorescently labeled anti-B220/
CD45R and anti-TCRb, and incubated with 7-amino-actinomy-
cin D (7AAD; 1 mg/ml). Uptake of 7AAD by dying B (B220+) and
T (TCRb+) cells was quantified by flow cytometry. The
percentage of viable cells was calculated by dividing
B220
+7AAD
2 or TCRb
+7AAD
2 by the total B220
+ or TCRb
+
cells at each time point. For BAFF- and anti-CD40-induced
survival, purified B cells were incubated at (7.5610
5 cells/ml) with
the indicated concentrations of BAFF or agonistic anti-CD40
(100 ng/ml) for 66 h, stained with fluorescently labeled anti-B220
and 7AAD, and analyzed by flow cytometry. To assess
proliferation, purified B cells (2.5610
5 cells/ml) were stimulated
with anti-m F(ab9)2 (Jackson ImmunoResearch Laboratories, Inc.)
or LPS (Sigma), and during the final 18 h of the 66 h period, DNA
synthesis was measured by adding 1 mCi
3H-thymidine to the
culture. The cells were then harvested and lysed, and the DNA
was transferred to a filtermat. The amount of incorporated
3H-
thymidine was quantified using a scintillation counter.
Immunoblotting and Transient Transfections
B cells, T cells, and MEFs were lysed in a buffer containing
20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 30 mM NaF, 2 mM sodium pyrophosphate supplemented
with Complete (Roche) protease inhibitor cocktail, and the
detergent-soluble lysate was collected after centrifugation. Lysates
were normalized to protein concentration, denatured in sample
buffer (50 mM Tris pH 6.8, 10% glycerol, 2% SDS, 2% b-
mercaptoethanol, and 0.04% bromophenol blue), resolved by
SDS-PAGE, and immunoblotted with the appropriate antibodies.
For knockdown studies, 3.0610
5 MEFs were plated in 60 mm cell
culture dishes and 16 h later transfected with 30 nM of Universal
Lo GC content non-targeting or c-IAP2 Stealth iRNA siRNA
using Lipofectamine RNAiMAX (Invitrogen) following the
manufacturer’s protocol. After 24 h the cells were washed twice
with phosphate-buffered saline (PBS) and lysed. For ectopic
expression studies, 293T cells were transfected with the indicated
plasmids using Lipofectamine 2000 (Invitrogen) following the
manufacturer’s protocol. Twenty-four hours later the cells were
harvested, washed with PBS, counted, and lysed in sample buffer.
In Vitro Protein Binding
Glutathione S-transferase (GST)-tagged proteins were expressed
in DH5a cells with 0.05 mM isopropyl-b-thiogalactopyranoside at
16uC for 20 h and lysed in 20 mM HEPES pH 7.5, 100 mM
NaCl, 1.5 mM MgCl2, 1% Triton X-100. The recombinant
proteins were purified from clarified lysates using glutathione
Sepharose 4B beads (Amersham Biosciences). The beads were
washed extensively and incubated with
35S-labeled TRAF2 that
had been translated in vitro using the TNT Quick Coupled
Transcription/Translation System (Promega) for 3 h at 4uCi n
binding buffer containing 120 mM NaCl, 10% glycerol, 1%
Triton X-100, and 50 mM Tris pH 7.5. The bead-bound
complexes were washed with the binding buffer, eluted with
sample buffer, and resolved by SDS-PAGE.
Adoptive Transfers
Equal number of splenic B cells purified from wild type
(CD45.1
+) and c-IAP2
H570A/H570A (CD45.2
+) knockin mice were
mixed and 10
7 cells were injected into the tail veins of RAG2-
deficient (CD45.2
+) mice. Forty-five days later the percentage of
wild type and c-IAP2
H570A/H570A B cells in the spleens and lymph
nodes was determined by staining cell suspensions with B220,
CD45.1, and CD45.2 and analyzed by flow cytometry. The ratio
was generated by dividing the percentage of c-IAP2
H570A/H570A B
cells by the percentage of wild type B cells.
Histology and Serum Immunoglobulin Titers
Mice were euthanized using CO2 inhalation and necropsies
were performed. A comprehensive set of organs and tissues were
collected and fixed in 10% neutral buffered formalin. Tissues were
paraffin-embedded, sectioned at 5 mm, and stained with hema-
toxylin and eosin. For lymphocytes, slides were stained with biotin-
conjugated anti-B220/CD45R or anti-CD3. The antigens were
B Cell Abnormalities in c-IAP2 E3-Defective Mice
PLoS Biology | www.plosbiology.org 11 October 2010 | Volume 8 | Issue 10 | e1000518retrieved by microwaving in EDTA (B220) or citrate buffer (CD3).
Detection of B220 was performed using the avidin-biotinylated
enzyme complex (Vector Laboratories) with 3,39-diaminobenzi-
dine (Sigma) as chromagen. Detection of CD3 was accomplished
using the Rabbit Elite kit (Vector Laboratories) using 3,39-
diaminobenzidine as chromagen. Slides were counterstained with
hematoxylin. Stained sections were evaluated by a boarded
veterinary pathologist. Serum immunoglobulin isotypes were
quantified by ELISA following the manufacturer’s protocol.
p values were calculated using GraphPad Prism and a two-tailed
t test.
Supporting Information
Figure S1 Absence of c-IAP2 E3-activity activates the
non-canonical NF-kB signaling pathway.
Found at: doi:10.1371/journal.pbio.1000518.s001 (0.27 MB TIF)
Figure S2 Targeting strategy for generating the
c-IAP2
H570A/H570A mice.
Found at: doi:10.1371/journal.pbio.1000518.s002 (0.19 MB TIF)
Figure S3 c-IAP2/MALT1 fusion protein lacks E3
activity.
Found at: doi:10.1371/journal.pbio.1000518.s003 (0.16 MB TIF)
Figure S4 Lymphoid development and homeostasis in
7–12-wk-old c-IAP2
H570A/H570A mice.
Found at: doi:10.1371/journal.pbio.1000518.s004 (0.60 MB TIF)
Figure S5 T cell hyperplasia in GALT of wild type and
c-IAP2
H570A/H570A mice.
Found at: doi:10.1371/journal.pbio.1000518.s005 (4.39 MB TIF)
Figure S6 Binding of in vitro translated and metaboli-
cally labeled TRAF2 to glutathione beads bound to
recombinant GST-tagged murine c-IAP2 and c-IAP2
H570A.
Found at: doi:10.1371/journal.pbio.1000518.s006 (0.10 MB
TIF)
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